The effects of rosiglitazone on endothelin,nitric oxide and C-reactive protein in patients with impaired glucose tolerance

Objective To observe the changes in endothelin(ET),nitric oxide(NO) and C-reactive protein(CRP) before and after the rosiglitazone therapy in patients with impaired glucose tolerance(IGT). Methods 72 IGT patients were divided randomly into 2 groups:rosiglitazone group(n = 45) and placebo group(n=27).15 weeks later,the efficacy of rosiglitazone was compared.Results The levels of ET, CRP were decreased and NO increased significantly in rosiglitazone group compared with those before treatment (ET 54.8±10.0 pg/ml vs 72.8±24.3 pg/ml,P0.01;CRP 4.58±0.38 mg/L vs 5.99± 0.85mg/L,P0.01;NO 41.0±10.0μmol/L vs 31.3±9.0μmol/L,P0.01)).However,the levels of ET,CRP and NO in placebo group did not change singnificantly (P0.05).Conclusions Rosiglitazone can singnificantly improve ET,NO,CRP level in IGT patients,which means an additional effect of rosiglitazone on the correlation of inflammation and endothelial disturbance.